Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) plans to switch to using Navidea’s Fluorine-18 labeled β-amyloid imaging candidate, NAV4694, from
C-labeled Pittsburgh Compound-B (PiB) for its comprehensive research initiative in Alzheimer’s disease and Mild Cognitive Impairment. Dr. Christopher C. Rowe, MD FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia, announced the changeover to NAV4694 at the World Wide Alzheimer's Disease Neuroimaging Initiative meeting in Boston, MA.
AIBL, a globally renowned, multi-disciplinary effort to investigate factors impacting the development of Alzheimer’s disease across Australia, has previously employed the widely-recognized PiB compound in its research. PiB is the PET imaging agent prototype for β-amyloid detection, and remains an accepted benchmark standard for studies investigating Alzheimer’s disease and differential diagnoses of dementia. Recently published results from a head-to-head study funded by AstraZeneca that directly compared PiB to NAV4694 demonstrated that NAV4694 displayed imaging characteristics nearly identical to those of PiB.
“Recent updates to appropriate use criteria allow for earlier diagnosis and therapeutic intervention in the diagnosis of probable Alzheimer’s disease, and we believe β-amyloid PET imaging will play an increasingly important role for clinicians investigating this disease,” said Dr. Rowe, lead author on the head-to-head study. “As the accepted benchmark β-amyloid imaging agent, PiB has an excellent performance profile, but issues around timing, logistics and costs make its routine use challenging. A β-amyloid imaging agent that is accessible and affordable and that can be reliably interpreted in a variety of clinical settings would be most pragmatic. Our studies with NAV4694 show that it mirrors the performance of PiB, and that we can therefore confidently make this changeover and begin using NAV4694 in our research.”